Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

被引:1
作者
Rosso, Annalisa [1 ]
Flacco, Maria Elena [1 ]
Cioni, Giovanni [1 ]
Tiseo, Marco [1 ]
Imperiali, Gianmarco [1 ]
Bianconi, Alessandro [2 ]
Fiore, Matteo [2 ]
Calo, Giovanna Letizia [1 ]
Orazi, Vittorio [1 ]
Troia, Anastasia [1 ]
Manzoli, Lamberto [2 ]
机构
[1] Univ Ferrara, Sch Publ Hlth, Dept Environm & Prevent Sci, Via Fossato Mortara 44, I-44121 Ferrara, Italy
[2] Univ Bologna, Sch Publ Hlth, Dept Med & Surg Sci, Via San Giacomo 12, I-40126 Bologna, Italy
关键词
chikungunya fever; chikungunya vaccine; VLA1553; MV-CHIK; immunogenicity; vaccine safety; meta-analysis; DOUBLE-BLIND; PARTICLE VACCINE; TOLERABILITY; PHASE-1;
D O I
10.3390/vaccines12090969
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several vaccines against chikungunya fever have been developed and tested, and one has been recently licensed. We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). We included trials retrieved from MedLine, Scopus, and ClinicalTrials.gov. The outcomes were the rates of seroconversion/seroresponse and serious adverse events (SAEs) after the primary immunization course. We retrieved a total of 14 datasets, including >4000 participants. All candidate chikungunya vaccines were able to elicit an immunogenic response in >= 96% of vaccinated subjects, regardless of the vaccination schedule and platform used, and the seroconversion/seroresponse rates remained high 6 to 12 months after vaccination for most vaccines. Four of the five candidate vaccines showed a good overall safety profile (no data were available for ChAdOx1 Chik), with no significant increase in the risk of SAEs among the vaccinated, and a low absolute risk of product-related SAEs. Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.
引用
收藏
页数:11
相关论文
共 38 条
  • [1] [Anonymous], 2023, FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants
  • [2] [Anonymous], 2019, Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
  • [3] [Anonymous], 2019, NCT03807843
  • [4] [Anonymous], 2019, NCT05065983
  • [5] [Anonymous], 2023, NCT05072080
  • [6] [Anonymous], 2011, NCT03635086
  • [7] Prevalence of chronic comorbidities in chikungunya: A systematic review and meta-analysis
    Badawi, Alaa
    Ryoo, Seung Gwan
    Vasileva, Denitsa
    Yaghoubi, Sahar
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 67 : 107 - 113
  • [8] Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial
    Bennett, Sean R.
    McCarty, James M.
    Ramanathan, Roshan
    Mendy, Jason
    Richardson, Jason S.
    Smith, Jonathan
    Alexander, Jeff
    Ledgerwood, Julie E.
    de Lame, Paul-Andre
    Tredo, Sarah Royalty
    Warfield, Kelly L.
    Bedell, Lisa
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (09) : 1343 - 1355
  • [9] The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines
    Bettis, Alison
    L'Azou Jackson, Maina
    Yoon, In-Kyu
    Breugelmans, J. Gabrielle J.
    Goios, Ana M.
    Gubler, Duane
    Powers, Ann
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (01):
  • [10] Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
    Chang, Lee-Jah
    Dowd, Kimberly A.
    Mendoza, Floreliz H.
    Saunders, Jamie G.
    Sitar, Sandra
    Plummer, Sarah H.
    Yamshchikov, Galina
    Sarwar, Uzma N.
    Hu, Zonghui
    Enama, Mary E.
    Bailer, Robert T.
    Koup, Richard A.
    Schwartz, Richard M.
    Akahata, Wataru
    Nabel, Gary J.
    Mascola, John R.
    Pierson, Theodore C.
    Graham, Barney S.
    Ledgerwood, Julie E.
    [J]. LANCET, 2014, 384 (9959) : 2046 - 2052